Northland Securities Comments on Alvotech FY2026 Earnings

Alvotech (NASDAQ:ALVO) – Investment analysts at Northland Securities issued their FY2026 EPS estimates for Alvotech in a report issued on Thursday, March 19th. Northland Securities analyst C. Byrnes anticipates that the company will earn ($0.08) per share for the year. The consensus estimate for Alvotech’s current full-year earnings is ($0.07) per share. Northland Securities also issued estimates for Alvotech’s FY2027 earnings at ($0.01) EPS.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.50). Alvotech had a net margin of 4.74% and a negative return on equity of 12.84%. The business had revenue of $173.20 million for the quarter, compared to the consensus estimate of $162.20 million.

A number of other analysts also recently issued reports on the company. Morgan Stanley set a $10.00 price target on Alvotech in a research report on Wednesday, December 3rd. Barclays initiated coverage on shares of Alvotech in a research report on Monday, December 8th. They issued an “underweight” rating and a $5.00 price objective on the stock. Zacks Research upgraded shares of Alvotech from a “strong sell” rating to a “hold” rating in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alvotech in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.60.

Alvotech Stock Down 1.4%

Shares of NASDAQ ALVO opened at $3.53 on Monday. The firm has a market capitalization of $1.06 billion, a P/E ratio of 35.30 and a beta of 0.16. The stock’s 50-day simple moving average is $4.53 and its two-hundred day simple moving average is $5.84. Alvotech has a twelve month low of $3.42 and a twelve month high of $11.85.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ALVO. Vanguard Group Inc. lifted its holdings in shares of Alvotech by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock worth $35,481,000 after acquiring an additional 114,255 shares during the last quarter. Legal & General Group Plc raised its position in Alvotech by 17.0% in the 2nd quarter. Legal & General Group Plc now owns 657,742 shares of the company’s stock worth $6,028,000 after purchasing an additional 95,331 shares during the period. Millennium Management LLC lifted its stake in Alvotech by 1,707.7% in the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock worth $1,832,000 after purchasing an additional 337,417 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Alvotech by 88.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after buying an additional 122,089 shares during the period. Finally, Geode Capital Management LLC boosted its position in Alvotech by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock valued at $1,308,000 after buying an additional 24,667 shares during the period.

Alvotech News Summary

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Q4 and FY‑2025 revenue beat and bullish 2026 outlook — Q4 revenue was $173M (+13% YoY) and FY revenue was $593M (+21% YoY); management reiterated 2026 revenue guidance of $650–700M and raised adjusted EBITDA guidance. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Positive Sentiment: Regulatory approvals, commercial launches and partner deals expand near‑term commercial runway — multiple biosimilars (e.g., AVT05, AVT03) cleared in Europe/UK, a marketing application accepted for AVT23, U.S. launch activity via partners (Selarsdi™), and supply/commercialization agreements with Sandoz for key territories. Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments
• Positive Sentiment: Balance sheet and leadership moves reduce execution risk — Alvotech raised ~\$300M, listed on Nasdaq Stockholm, expanded R&D via acquisitions, and appointed Lisa Graver as CEO and other senior hires to support scaling. Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO
• Neutral Sentiment: U.S. approvals expected late‑2026 but management says they will have minimal 2026 topline impact — this tempers upside from potential FDA wins this year. Alvotech Q4 2025 and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage and price‑target dispersion — several buy/overweight ratings and median analyst target near \$9 show upside in some forecasts, but targets vary widely—expect mixed analyst reactions. Alvotech Reports Q4 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Short‑interest data reported for March appears inconsistent/invalid (entries show 0 shares and NaN increases), so short‑interest signals are currently unreliable. (Multiple short‑interest notices 3/18–3/20)
• Negative Sentiment: EPS missed consensus — reported EPS of $0.03 vs. consensus ~$0.13, which can pressure sentiment despite the revenue beat. Alvotech earnings summary
• Negative Sentiment: FDA inspection observations remain an overhang — management says improvements are underway and resubmissions are planned for Q2 2026, but regulatory risk could delay U.S. commercialization and investor confidence. Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).